Advances in the study of pyrotinib for the treatment of HER2-positive breast cancer
{{output}}
HER2-positive breast cancer is characterized by aggressive tumor biology and intrinsic resistance to conventional therapies, underscoring the need for novel targeted treatment approaches. Pyrotinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), cova... ...
